# Grail

Type: Company (GRAL)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/grail
Canonical HTML page: https://getfinancebrief.com/entity/grail

## Timeline

- **2026-03-22**: Market Outperformance — Financial media highlights Grail as the week's top performer in the diagnostics sector.
- **2026-03-20**: Volume Surge — Stock sees highest trading volume in six months as institutional buyers return.
- **2026-03-18**: TD Cowen Upgrade — Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
- **2026-03-16**: Market Low — GRAL stock hits a 52-week low amid heavy selling pressure.
- **2026-03-13**: CEO Transition — Bob Ragusa steps down as CEO following reports of a trial setback.
- **2026-02-20**: Candel Public Offering — Candel Therapeutics prices $100M public offering at $5.45 per share.
- **2026-02-20**: Trial Data Release — Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
- **2026-02-20**: GDP Release — U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
- **2026-02-19**: Grail Earnings — Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.

## Recent coverage (2 stories)

### Grail Shares Surge as Market Reassesses NHS Trial Setback and TD Cowen Upgrade
2026-03-22 12:13:11 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Full story: https://getfinancebrief.com/story/grail-gral-stock-rally-march-2026

### US Futures Rebound as Markets Await Pivotal Q4 GDP Growth Data
2026-02-20 12:42:09 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.
Full story: https://getfinancebrief.com/story/us-futures-rebound-gdp-data-grail-candel

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.